FOCUS

There are over 300 million people around the globe
who live with chronic inflammatory conditions.

MUSCLOSKELETAL

Osteoarthritis (OA): OA is a chronic, progressive joint disease that affects over 30 million people in the United States and over 300 million people worldwide. OA causes the articular cartilage to break down, resulting in loss of joint flexibility, bone degeneration and inflammation. One of the most debilitating effects of OA is the chronic pain associated with the condition – even the seemingly most simple tasks often become unmanageable. As a result, this pain takes a significant toll on a patient’s quality of life.

 

OA also weighs heavily on the healthcare system, with incremental costs nearing $137 billion a year. Treatment options are varied but rarely address the underlying root cause of the disease. At later stages, options might include addictive pain medicines or surgery, so physicians often struggle to find solutions to treat the pain associated with OA effectively and safely. This, along with a growing number of patients affected due to rising obesity rates and aging populations, magnifies the need for a new alternative solution.   

 

Xalud has successfully completed three phase 1 studies (NCT03282149, NCT03477487 and NCT03769662) and initiated a multinational, double-blind, placebo-controlled phase 2 study (NCT04124042) evaluating the safety and efficacy of XT-150 in adult participants with moderate-to-severe pain due to OA of the knee. Visit our Clinical Trials page for more information on Xalud’s active studies.

 

For additional information on OA and its unmet need, please visit:

 

Facet Joint Syndrome: Facet joint syndrome is a painful, progressive inflammatory condition affecting the vertebral joints in the back and neck. Damage to these synovial joints due to aging or trauma may result in chronic neck or back pain. The prevalence of lumbosacral facet joint syndrome is quite common – lumber facet joints are likely a source of chronic low back pain for up to 13 million people in the United States.  Xalud is about to begin clinical trials evaluating XT-150 for the treatment of facet joint syndrome.

NEUROLOGIC INDICATIONS

Neuropathic Pain: The estimated prevalence of neuropathic pain in the US is approximately 10%. This debilitating condition results from injury or damage to nerves in the body when an ensuing cycle of injury is established and reinforced, resulting in persistent, pathological pain. Xalud is currently evaluating XT-150 for the treatment of neuropathic pain from central and peripheral etiologies in IND-enabling studies.

 

Peripheral Induced Neuropathic Pain - Lumbar/Cervical Radiculitis: Pain caused by radiculitis, compression of a nerve root as it exits the spinal column, affects approximately 12 million adults in the United States. Current treatment can include surgical management, which is often painful, costly and only partially resolves pain symptoms. Xalud has a double-blind, placebo-controlled phase 1 study ongoing (NCT04466410) of XT-150 in adults with chronic neuropathic radicular pain.

 

Multiple Sclerosis (MS): More than 2.8 million people worldwide are estimated to have MS, with approximately 1 million in the US alone. MS is characterized by a breakdown of the blood-brain barrier, demyelination and axonal degeneration. While there are certain disease-modifying treatments for the disease, there remains a large unmet need to address the MS patient experience. We are currently evaluating the potential of XT-150 as a treatment for MS.

Amyotrophic Lateral Sclerosis (ALS): ALS, also known as Lou Gehrig’s disease, is a rare disease that affects approximately 200,000 people worldwide, with 16,000 estimated in the US. It is a progressive disease characterized by degeneration of the motor neurons in the brain and spinal cord. Currently available treatments do not halt the progression of ALS and median survival from onset is 2-4 years. We are currently evaluating the potential of XT-150 as a treatment for ALS.

OTHER

Ophthalmic: There are millions of people diagnosed with inflammatory ophthalmic conditions such as uveitis and dry eye disease (DED). Xalud is currently evaluating strategies and approach for the use of DNA plasmid-based IL-10 therapy in the treatment of various ophthalmic conditions.

 

Dermal: Dermal conditions such as atopic dermatitis, eczema and psoriasis are caused by inflammation and affect millions of people across the United States. Xalud is currently evaluating strategies and approach for the use of DNA plasmid-based IL-10 therapy in the treatment of various dermal conditions.

knee3.jpg